INMB
INmune Bio Inc
1.90$
-0.5%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -9.1% | -17.8% | +12.0% | +0.6% | -25.0% | -4.5% | -0.3% | -11.5% | -3.0% | -20.2% | +4.0% | |
| – | -12.4% | -25.3% | +19.0% | +1.0% | -36.8% | -7.5% | +71.9% | -14.9% | -2.6% | -23.6% | +4.3% | |
| – | -14.3% | -27.5% | +19.5% | +8.0% | -37.6% | -7.6% | +72.6% | -16.9% | -10.8% | -13.7% | -13.8% | |
| – | -14.3% | -27.5% | +19.5% | +8.0% | -37.6% | -7.6% | +72.6% | -16.9% | -10.8% | -13.7% | -13.8% | |
| – | +7.9% | +10.2% | +26.9% | -58.4% | -0.8% | +0.5% | +52.2% | +14.3% | +84.3% | -83.0% | +519.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | – | – | – | – | – | |
| – | +5.0% | -5.6% | -13.7% | -8.2% | -47.1% | +8.9% | +8.5% | -9.5% | +10.6% | -29.8% | +4.7% | |
| – | +28.6% | -5.5% | -13.7% | -8.2% | -47.8% | +9.8% | +8.3% | -14.3% | +14.4% | -36.0% | +9.3% | |
| – | -0.7% | -24.5% | -32.6% | -48.5% | -94.7% | +4.3% | +50.7% | +107.7% | +36.3% | +13.0% | +15.3% | |
| – | +115.0% | +17.6% | -0.1% | +14.7% | -38.3% | +11.2% | +7.6% | -12.5% | +13.0% | -40.0% | +9.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -14.7% | -23.9% | +27.8% | +4.3% | -17.0% | -7.6% | -2.7% | -12.1% | -7.3% | -16.6% | +3.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -0.3% | +0.4% | +7.1% | +4.6% | +10.4% | +1.0% | +3.6% | +14.1% | +0.0% | +0.0% | +0.5% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.